APOE and myeloproliferative disorder: To assess the impact of TG101348 on hematopoiesis, we administered vehicle or TG101348 to WD-fed WT or Apoe−/− mice at a dose that sustained the plasma concentration above the cellular IC50 and effectively reduced myelopoiesis, hematocrit, and leukocytosis in a murine model of MPN induced by hematopoietic Jak2V617F expression [18].